Inebilizumab (Genetical Recombination)



Inebilizumab is a recombinant humanized monoclonal antibody composed of complementarity-determining regions derived from mouse anti-human CD19 monoclonal antibody, human framework regions and human IgG1 constant regions. Inebilizumab is produced in glycoprotein 6-α-L-fucosyltransferase-deficient Chinese hamster ovary cells. Inebilizumab is a glycoprotein (molecular weight: ca. 149,000) composed of 2 H-chains (γ1-chains) consisting of 451 amino acid residues each and 2 L-chains (κ-chains) consisting of 218 amino acid residues each.

[1299440-37-1]